Masimo has received CE Mark approval for its Radius-7, the first rainbow signal extraction technology (SET) based noninvasive wearable, wireless monitor for Root patient monitoring and connectivity platform.
The company has also announced the limited market release of Radius-7, claimed to allow early identification of clinical deterioration, while offering patients continuous monitoring with freedom of movement.
Go deeper with GlobalData
Featuring rainbow SET technology, Radius-7 with Root alerts clinicians at the bedside or remotely, through the Masimo Patient SafetyNet remote monitoring and notification system.
Radius-7 can be attached to patient’s arm or can be placed alongside the patient’s bet for continuous monitoring.
The device can give alerts about critical changes in a patient’s oxygen saturation, pulse rate, respiration rate, or haemoglobin that may indicate pulmonary, cardiac, or internal bleeding problems.
With no need to disconnect and reconnect the cable to get out of bed, the device reduces the need for nursing assistance.
Radius-7 is connected through Bluetooth back to Root or with upgradeable WiFi for long-range communication, ensuring that the patients are monitored continuously and connected to the caregivers.
Masimo founder and CEO Joe Kiani said: "In the past, wearable patient monitoring offered only limited measurements that were often plagued by false alarms.
"Radius-7 allows untethered clinically relevant patient monitoring.
"We expect Radius-7 and Root to change how hospitals think about monitoring, ushering in a new level of patient safety."
Currently, Radius-7 is not available for sale in the US.
Image: The Radius-7 offers continuous, noninvasive patient monitoring with comfort and freedom of movement. Photo: courtesy of Marketwired/ Masimo.
